Title: Exclusive Endorsement and CPT Billing Codes for High-Pressure Medical Cryotherapy Device Introduction
On June 14th, 2022, New York Cryogen Inc. achieved a groundbreaking milestone in the field of cryotherapy. The company received full endorsement from the prestigious American Medical Association (AMA) and obtained exclusive Current Procedural Terminology (CPT) billing codes for their high-pressure medical cryotherapy device and treatment modality. This remarkable achievement marks a significant advancement in the history of cryotherapy, opening new possibilities for medical practitioners and patients alike. Revolutionizing Cryotherapy New York Cryogen Inc. has been diligently working on the development of two high-powered, high-pressure cryotherapy medical devices. These devices can be effectively used in private practices or institutional settings, offering applications for post-operative care and addressing chronic or acute pain. With the AMA’s endorsement and the issuance of exclusive CPT billing codes, New York Cryogen Inc. has solidified its position as a pioneer in the field of cryotherapy.
The AC-130 Viper: A Cutting-Edge Medical Cryotherapy Device
Authorized users who have the AC-130 Viper, the exclusive high-pressure medical cryotherapy device, can now take advantage of the newly issued billing codes. This device is nearing completion and is expected to be available for distribution in the beginning of the 4 quarter of 2023. Designed with precision and efficiency in mind, the AC-130 Viper offers unparalleled therapeutic benefits and sets new standards for cryotherapy treatments. The AC-130 Hurricane: A Prototype on the Horizon In addition to the AC-130 Viper, New York Cryogen Inc. is also in the final stages of developing the AC-130 Hurricane. While still in the prototype phase, this device is nearly 100% complete. Once completed, the AC-130 Hurricane will provide medical practitioners with an added choice for delivering high-pressure cryotherapy treatments. Its impending release further highlights New York Cryogen Inc.’s commitment to pushing the boundaries of cryotherapy technology.
Leasing Agreements for Institutional and Private Practice Use
To ensure widespread accessibility of their medical devices, New York Cryogen Inc. will be offering leasing agreements to both institutional and private practice users. This approach enables medical professionals to integrate high-pressure cryotherapy into their treatment options without the burden of significant upfront costs. By facilitating easy access to these innovative devices, New York Cryogen Inc. aims to foster the widespread adoption of their cryotherapy modality. Robust Reimbursement Opportunities New York Cryogen Inc. has successfully negotiated reimbursement agreements with Medicare and all major private insurance companies. This positive outcome ensures that healthcare providers using their exclusive billing codes will be able to obtain robust reimbursement for cryotherapy treatments. The financial viability of integrating cryotherapy into medical practices is thus enhanced, creating an incentive for practitioners to explore the benefits of this innovative treatment modality.
Conclusion
New York Cryogen Inc.’s recent achievement of full endorsement from the AMA and the exclusive issuance of CPT billing codes for their high-pressure medical cryotherapy device signifies a pivotal moment in the field of cryotherapy. With the imminent release of the AC-130 Viper and the ongoing development of the AC-130 Hurricane, New York Cryogen Inc. is poised to revolutionize the way cryotherapy is used in healthcare. By offering leasing agreements and securing robust reimbursement opportunities, the company aims to make high-pressure cryotherapy accessible to a wide range of medical practitioners and patients globally.
***If you would like updates, please fill out the form below you will placed on our notification distribution list.